Atrium Therapeutics Inc. Company Profile
NASDAQ: RNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 1:01 PM ET
Atrium Therapeutics at a glance
Atrium Therapeutics Inc. (NASDAQ: RNA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. Atrium Therapeutics is led by Ms. Kathleen P. Gallagher. At a market capitalization of $141.3 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0002093101, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Atrium Therapeutics do?
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Atrium Therapeutics Inc.
- Ticker
- NASDAQ: RNA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Kathleen P. Gallagher
- Headquarters
- 10578 Science Center Drive, San Diego, CA, United States
- Phone
- 619 876 0700
- Website
- atriumtherapeutics.com
- Market cap
- $141.29M
- SEC CIK
- 0002093101
Companies similar to Atrium Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OGIOrganigram Global Inc. | 0.9499 | -0.13% | $136.93M | vs RNA |
| TLSATiziana Life Sciences Ltd. | 1.17 | +3.10% | $148.26M | vs RNA |
| BGMBGM Group Ltd. Class A | 9.69 | 0.00% | $129.40M | vs RNA |
| KRROKorro Bio Inc. | 10.51 | -0.66% | $154.77M | vs RNA |
| CLLSCellectis S.A. ADR | 1.26 | +0.40% | $126.42M | vs RNA |
| HURATuHURA Biosciences Inc. | 1.98 | +2.59% | $126.18M | vs RNA |
| SPRBSpruce Biosciences Inc. | 43.55 | -4.38% | $125.15M | vs RNA |
| NERVMinerva Neurosciences Inc | 3.30 | +2.48% | $157.57M | vs RNA |